ARTICLE SUMMARY:
Liquid biopsy play Thrive Earlier Detection launched last year with a $110 million Series A, the largest initial round for a diagnostics company since Verily’s $800 million haul in 2017. Thrive boasts groundbreaking science and a top-tier executive team, but the start-up faces many challenges in bringing its multi-cancer screening test for asymptomatic patients into primary care. We also cover PQ Bypass’ PAD solution and new investment portal Bioverge.
